You are here: Industry Insights > sales

News List

Top 10 Sales Volume of New Drugs of Traditional Chinese Medicine: Behind the Numbers - Only 2 Out of 29 Surpassed RMB 100 Million in Sales Xiao Yan
March 14, 2025
From 2016 - 2024, TCM new drugs made progress but lagged in sales. This article analyzes reasons and explores future directions.
Sales volume of Dupixent reaching USD 5.35 billion in H1 of the year, setting off a R&D boom of IL-4R in China PharmaSources/Yefenghong
August 28, 2023
Under the influence of Dupixent, there is a R&D boom of IL-4 targets in China.
35 per 100 CNY Earned for Marketing, How Much is the Sales Expense Ratio of Chinese Pharmaceutical Companies? PharmaSources/Caicai
August 17, 2023
High sales expenses not only increase the cost of medical treatment and medication, but also affect the healthy development of the domestic pharmaceutical industry. Therefore, anti-corruption is imperative and imminent.
What is the Confidence of this Pharmaceutical Company To Target its Sales Peak of CNY 10 Billion? Xiaobin/PharmaSources
August 07, 2023
Recently, at Everest Medicines' investor exchange activities, the management led by CEO Luo Yongqing put forward the target of "realizing the marketing of four commercial products in a short time, with a sales peak of CNY 10 billion".
With an annual sales volume of RMB 666 million, Sevelamer Carbonate Tablets of Dr. Reddy's Laboratories were approved in China Caicai/PharmaSources
May 22, 2023
On May 8, the NMPA official website revealed that the type 5.2 chemical drug, Sevelamer Carbonate Tablets, of Dr. Reddy's Laboratories had been approved for marketing in China.
The sales of the BTK inhibitor reached at least USD 11 billion worldwide in 2021 PharmaSources/Caicai
March 16, 2022
In today's new drug world, BTK inhibitor stands out as a member of chemical drugs in a context where biologics yield unusually brilliant results.
AbbVie's performance in 2021: a new high in total revenue, with the sales volumes of Hu-mi-ra topping USD 20 billion PharmaSources/Yi
February 22, 2022
On February 2, AbbVie announced its performance in the fourth quarter and full year of 2021, representing an annual revenue of USD 56.197 billion (+22.7%) and R&D investment of USD 7.084 billion (+8%).
In 2021, the sales volume of Innovent's PD-1 exceeded RMB 3 billion PharmaSources/Caicai
February 21, 2022
Chinese PD-1 also sells well. According to the quarterly sales data of Innovent's sintilimab (trade name: Tyvyt), its sales volume was about RMB 3.1 billion in 2021 (nominal sales revenue).
Junshi’s Anti-PD-1 Drug Achieved Sales of RMB1.3 Billion in 2020 PharmaSources/Caicai
March 12, 2021
Junshi Biosciences has recently announced its 2020 annual performance preview, according to which, it achieved operating income of RMB1.595 billion, up 105.77% year on year, mainly thanks to the sales revenue growth of its anti-PD-1 drug.
Qilu Pharmaceutical Achieved Staggering Sales of Bevacizumab of RMB1.8 Billion in 2020 PharmaSources/Caicai
March 04, 2021
According to industry news, Qilu Pharmaceutical achieved sales of bevacizumab (trade name: Ankeda) of about RMB1.8 billion in 2020.